Blood advances
Improved survival and healthcare utilization with CAR-T vs historical care in relapsed-refractory large B-cell lymphoma.
Tiana Kordbacheh, Kelvin Kw Chan, Michael Crump, Zharmaine Ante, Ning Liu, Mahmood Aminilari, Inna Y Gong, Sita Bhella, Abi Vijenthira, John Kuruvilla, Robert Kridel, Christine Chen, Vishal Kukreti, Chloe Yang, David Hodgson
Published: 202610.1182/bloodadvances.2025017401
Abstract
Anti-CD19 Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies have been funded in Canada for relapsed-refractory large B-cell lymphoma (RR-LBCL) after two lines of systemic therapy since late 2019. Real-world outcome data have been limited by la…
Preview only. Read the full abstract at the source